Gilead Sciences IncGILD
Recorded
Gilead Sciences Inc Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration35 min
Key takeaways
- Gilead's management highlighted their strategy to diversify beyond their stronghold in virology into oncology and inflammation.
- In virology, Gilead launched the combination of Bictegravir and Lanacepavir as a daily oral treatment for a specific patient population, known as Slenvo.
- They presented data on the Isletravir Lanacepavir combination as a once-weekly oral treatment and are working on longer duration treatments up to once every six months.
- Gilead's HIV prevention portfolio includes a submitted once-weekly Lanacepavir, a launched once every six months option, and clinical trials for once every 12 months.
- In oncology, the acquisition of Arcelix brought needle cell therapy fully into Gilead, with strong data in fourth line plus multiple myeloma and ongoing studies in earlier lines.
- Gilead expects approval for the needle cell therapy in the fourth line plus setting towards the end of the year.
- They are developing next generation CAR T therapies, including bispecific CAR Ts targeting CD19 and CD20, and exploring expansion into inflammation and neuroinflammation, as well as in vivo CAR T therapies for the longer term.
- The acquisition of Tubulus added TUB40 to their portfolio, focused on ovarian cancer, with data showing a 60% objective response rate at ASCO.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring